Enanta Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Thank you for joining us again for the JMP Securities Life Science Conference. Next company we have is Enanta Pharmaceuticals, and we have Jay Luly, the CEO of Enanta. So thanks for joining us, Jay.
Questions & Answers
I'm going to jump right in on the programs. You guys are focused on small molecules, antivirals. So let's start talking about COVID, your lead program there, EDP-235. We're expecting Phase 1, first-in-human Phase 1 results next month. Maybe just walk us through what we can expect there. We kind of expected the results this month, and they've moved to next month. So maybe you can describe why their timeline shifted a little bit.
Sure. So thanks for the opportunity to chat today. Before I begin, I want to remind you I'll be making some forward-looking statements, and for a summary of the risks associated with these statements, please see our filings on sec.gov and on our website.
Yes.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |